A Randomized Controlled Trial of Prison-initiated Buprenorphine: Prison Outcomes and Community Treatment Entry

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2014 Jun 26

PMID 24962326

Citations 57

Authors

Michael S Gordon

Timothy W Kinlock

Robert P Schwartz

Terrence T Fitzgerald

Kevin E OGrady

Frank J Vocci

Affiliations

Soon will be listed here.

Abstract

Background: Buprenorphine is a promising treatment for heroin addiction. However, little is known regarding its provision to pre-release prisoners with heroin dependence histories who were not opioid-tolerant, the relative effectiveness of the post-release setting in which it is provided, and gender differences in treatment outcome in this population.

Methods: This is the first randomized clinical trial of prison-initiated buprenorphine provided to male and female inmates in the US who were previously heroin-dependent prior to incarceration. A total of 211 participants with 3-9 months remaining in prison were randomized to one of four conditions formed by crossing In-Prison Treatment Condition (received buprenorphine vs. counseling only) and Post-release Service Setting (at an opioid treatment center vs. a community health center). Outcome measures were: entered prison treatment; completed prison treatment; and entered community treatment 10 days post-release.

Results: There was a significant main effect (p=.006) for entering prison treatment favoring the In-Prison buprenorphine Treatment Condition (99.0% vs. 80.4%). Regarding completing prison treatment, the only significant effect was Gender, with women significantly (p<.001) more likely to complete than men (85.7% vs. 52.7%). There was a significant main effect (p=.012) for community treatment entry, favoring the In-Prison buprenorphine Treatment Condition (47.5% vs. 33.7%).

Conclusions: Buprenorphine appears feasible and acceptable to prisoners who were not opioid-tolerant and can facilitate community treatment entry. However, concerns remain with in-prison treatment termination due to attempted diversion of medication.

Citing Articles

Barriers and facilitators to community pharmacist-provided injectable naltrexone for formerly incarcerated individuals during community reentry.

Chladek J, Chui M Explor Res Clin Soc Pharm. 2025; 17:100561.

PMID: 39896177 PMC: 11786854. DOI: 10.1016/j.rcsop.2025.100561.

Extended-release buprenorphine induction in opioid non-tolerant incarcerated individuals.

Gordon M, Blue T, Vocci F, Mitchell S, Wenzel K, Fishman M Drug Alcohol Depend Rep. 2025; 12():100261.

PMID: 39829944 PMC: 11740793. DOI: 10.1016/j.dadr.2024.100261.

Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review.

Chladek J, Chui M Front Public Health. 2024; 12:1377193.

PMID: 38803812 PMC: 11128549. DOI: 10.3389/fpubh.2024.1377193.

Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes.

Bovell-Ammon B, Yan S, Dunn D, Evans E, Friedmann P, Walley A JAMA Netw Open. 2024; 7(3):e242732.

PMID: 38497959 PMC: 10949092. DOI: 10.1001/jamanetworkopen.2024.2732.

Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities.

Handanagic S, Broz D, Finlayson T, Kanny D, Wejnert C Drug Alcohol Depend. 2024; 257:111251.

PMID: 38457965 PMC: 11031279. DOI: 10.1016/j.drugalcdep.2024.111251.

References

Rosenblum A, Cleland C, Fong C, Kayman D, Tempalski B, Parrino M . Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011; 2011:948789. PMC: 3136171. DOI: 10.1155/2011/948789. View

Dasgupta N, Bailey E, Cicero T, Inciardi J, Parrino M, Rosenblum A . Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010; 11(7):1078-91. DOI: 10.1111/j.1526-4637.2010.00877.x. View

Johanson C, Arfken C, di Menza S, Schuster C . Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2011; 120(1-3):190-5. DOI: 10.1016/j.drugalcdep.2011.07.019. View

Chandler R, Fletcher B, Volkow N . Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA. 2009; 301(2):183-90. PMC: 2681083. DOI: 10.1001/jama.2008.976. View

Strang J, Gossop M, Heuston J, Green J, Whiteley C, Maden A . Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison. Addiction. 2006; 101(8):1125-32. DOI: 10.1111/j.1360-0443.2006.01475.x. View

Binswanger I, Blatchford P, Lindsay R, Stern M . Risk factors for all-cause, overdose and early deaths after release from prison in Washington state. Drug Alcohol Depend. 2011; 117(1):1-6. DOI: 10.1016/j.drugalcdep.2010.11.029. View

Greenfield S, Back S, Lawson K, Brady K . Substance abuse in women. Psychiatr Clin North Am. 2010; 33(2):339-55. PMC: 3124962. DOI: 10.1016/j.psc.2010.01.004. View

Levasseur L, Marzo J, Ross N, Blatier C . [Frequency of re-incarcerations in the same detention center: role of substitution therapy. A preliminary retrospective analysis]. Ann Med Interne (Paris). 2002; 153(3 Suppl):1S14-9. View

Merrall E, Kariminia A, Binswanger I, Hobbs M, Farrell M, Marsden J . Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010; 105(9):1545-54. PMC: 2955973. DOI: 10.1111/j.1360-0443.2010.02990.x. View

10.

Murphy D, Hser Y, Huang D, Brecht M, Herbeck D . Self-report of Longitudinal Substance Use: A Comparison of the UCLA Natural History Interview and the Addiction Severity Index. J Drug Issues. 2011; 40(2):495-516. PMC: 3013623. DOI: 10.1177/002204261004000210. View

11.

Binswanger I, Nowels C, Corsi K, Glanz J, Long J, Booth R . Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012; 7:3. PMC: 3414824. DOI: 10.1186/1940-0640-7-3. View

12.

Monte A, Mandell T, Wilford B, Tennyson J, Boyer E . Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2010; 28(3):226-31. DOI: 10.1080/10550880903014767. View

13.

McLellan A, Kushner H, Metzger D, Peters R, Smith I, Grissom G . The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9(3):199-213. DOI: 10.1016/0740-5472(92)90062-s. View

14.

Magura S, Lee J, Hershberger J, Joseph H, Marsch L, Shropshire C . Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2008; 99(1-3):222-30. PMC: 2658719. DOI: 10.1016/j.drugalcdep.2008.08.006. View

15.

Krinsky C, Lathrop S, Brown P, Nolte K . Drugs, detention, and death: a study of the mortality of recently released prisoners. Am J Forensic Med Pathol. 2009; 30(1):6-9. DOI: 10.1097/PAF.0b013e3181873784. View

16.

Kanato M . Drug use and health among prison inmates. Curr Opin Psychiatry. 2008; 21(3):252-4. DOI: 10.1097/YCO.0b013e3282fc985c. View

17.

Stallwitz A, Stover H . The impact of substitution treatment in prisons--a literature review. Int J Drug Policy. 2007; 18(6):464-74. DOI: 10.1016/j.drugpo.2006.11.015. View

18.

Dolan K, Shearer J, White B, Zhou J, Kaldor J, Wodak A . Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005; 100(6):820-8. DOI: 10.1111/j.1360-0443.2005.01050.x. View

19.

Taxman F, Perdoni M, Harrison L . Drug treatment services for adult offenders: the state of the state. J Subst Abuse Treat. 2007; 32(3):239-54. PMC: 2266078. DOI: 10.1016/j.jsat.2006.12.019. View

20.

Fazel S, Bains P, Doll H . Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006; 101(2):181-91. DOI: 10.1111/j.1360-0443.2006.01316.x. View